Patents by Inventor Francois Nortier

Francois Nortier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nitrogen-rich macrocyclic ligands, chelation complexes thereof, and process for selective chelation of radioactive bismuth ions with the ligands
    Patent number: 10450336
    Abstract: Selective chelation of bismuth radionuclide ions from a mixture including actinium radionuclide ions involves exposing a ligand to an aqueous solution that includes bismuth radionuclide ions and actinium radionuclide ions under conditions whereby the bismuth radionuclide ions selectively chelate to the ligand for form cationic complexes of the bismuth radionuclide ions. and separating the cationic complexes of the bismuth radionuclide ions from the actinium radionuclide ions. The ligands have a structure based on a 12-membered cyclen ring and may include pendant functional groups that can be derivatized with biological targeting vectors for targeted alpha therapy.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: October 22, 2019
    Assignee: Triad National Security, LLC
    Inventors: Justin Wilson, Eva Birnbaum, Kevin John, Francois Nortier, Michael Fassbender, Valery Radchenko, Jonathan Ward Engle
  • NITROGEN-RICH MACROCYCLIC LIGANDS, CHELATION COMPLEXES THEREOF, AND PROCESS FOR SELECTIVE CHELATION OF RADIOACTIVE BISMUTH IONS WITH THE LIGANDS
    Publication number: 20150344508
    Abstract: Selective chelation of bismuth radionuclide ions from a mixture including actinium radionuclide ions involves exposing a ligand to an aqueous solution that includes bismuth radionuclide ions and actinium radionuclide ions under conditions whereby the bismuth radionuclide ions selectively chelate to the ligand for form cationic complexes of the bismuth radionuclide ions. and separating the cationic complexes of the bismuth radionuclide ions from the actinium radionuclide ions. The ligands have a structure based on a 12-membered cyclen ring and may include pendant functional groups that can be derivatized with biological targeting vectors for targeted alpha therapy.
    Type: Application
    Filed: May 4, 2015
    Publication date: December 3, 2015
    Applicant: Los Alamos National Security, LLC
    Inventors: Justin Wilson, Eva Birnbaum, Kevin John, Francois Nortier, Michael Fassbender, Valery Radchenko, Jonathan Ward Engle